Archived

RNA Modifications Driving Oncogenesis (RNAMoDO; U01 Clinical Trial Not Allowed)

Federal funding opportunity RFA-CA-24-029 from National Institutes of Health (Department of Health and Human Services).

Posted: July 29, 2024
Closed: November 4, 2024
Cost sharing: No
Instrument: Cooperative Agreement
Assistance listing: 93.394, 93.395, 93.396, 93.399, 93.393
Category: Education, Health
Archives: December 10, 2024

Program funding history

Awards made under Assistance Listing 93.394 (one of 5 on this opportunity) across FY2025–FY2027, from public federal spending records.

FY2025 obligated: $595.6M
FY2026 obligated: $548.5M
FY2027 (to date) obligated: $0
Awards in window: 1,877

Top recipients: Regents of the University of California, San Francisco, the, Fred Hutchinson Cancer Center, The Johns Hopkins University, The Leland Stanford Junior University, The Univeristy of Texas M.d. Anderson Cancer Center

Source: USAspending.gov · refreshed October 2026 · Program page: awards, recipients and the opportunities under this listing →

This opportunity is archived. Applications are no longer accepted. Similar grants are listed below, and the free Tuesday digest carries the next ones like it.

Synopsis

The overarching objective of this concept is to promote mechanistic research in the emerging area of RNA modifications that drive oncogenesis, with a focus on the central role of RNA modifications in translational reprogramming of cancer cells. RNA modifications have been recognized to exert a substantial impact on gene expression and function and their de-regulation has been linked to the cancer phenotype. In particular, recent insights point to a crucial role for mRNA, tRNA, and rRNA modifications in translational reprogramming during tumor initiation, progression, and adaptation to therapy. However, the molecular mechanisms underlying this reshaping of the translatome caused by dynamic changes in RNA modifications, and especially the interplay between different RNA modifications within and across RNA molecules during translation, are not understood and represent the focus of this initiative. Historically, the research community has largely pursued investigations of RNA modifications by studying single RNA species and modification types. However, elucidating how dysregulation of mRNA, tRNA, and rRNA modifications reprograms translation to drive oncogenesis is not likely feasible for any single research lab, but will require the combination of expertise in mRNA, tRNA and rRNA biology, translational regulation, and cancer research. To stimulate progress in this emerging field, the RNAMoDO program will support collaborative research projects, preferably using an MPI structure, on how modifications in mRNA, tRNA, and rRNA molecules can drive the oncogenic process through translational reprogramming. To be responsive to the NOFO, each project will also explore the impact of interactions between modifications residing on the same or different RNA molecules during translation.

Who can apply

County governments
Private institutions of higher education
State governments
Others (see text field entitled "Additional Information on Eligibility" for clarification)
Public housing authorities/Indian housing authorities
For profit organizations other than small businesses
Native American tribal governments (Federally recognized)
Special district governments
Independent school districts
Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
Native American tribal organizations (other than Federally recognized tribal governments)
Public and State controlled institutions of higher education
City or township governments
Small businesses

Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Organizations) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed.

The official record

Grants.gov published the official terms and dates of this opportunity; this page keeps them as they were listed.

View on Grants.gov Full announcement

Agency contact: National Institutes of Health · [email protected] · 301-402-2541

New to federal funding? How to read an announcement · Who can apply · How grants work

Tell me when this program posts again

This round has closed. One email the morning after this program is posted again under a new number (we watch for about two years), and one more about a week before that round closes (the next morning, if it is already closer than that). That is all this sends — it is not a newsletter signup.

Stored once per grant, used only for this watch’s emails; every one carries a one-click unsubscribe. Privacy

Get grants like this every Tuesday — free

One email a week: the biggest new federal grants and what’s closing soon — the same list for everyone. Unsubscribe any time.

No spam, ever. Privacy

Similar grants

Sustained Support for Informatics Technologies for Cancer Research and Management (U24 Clinical Trial Optional)
RFA-CA-27-021 · National Institutes of Health · closes October 19, 2026
Advanced Development of Informatics Technologies for Cancer Research and Management (U24 Clinical Trial Optional)
RFA-CA-27-020 · National Institutes of Health · closes October 19, 2026
Developing novel theory and methods for understanding the genetic architecture of complex human traits (R01 Clinical Trial Not Allowed)
PAR-25-255 · National Institutes of Health · closes November 5, 2026
Secondary Analysis and Integration of Existing Data to Elucidate Cancer Risk and Related Outcomes (R01 Clinical Trial Not Allowed)
PAR-25-095 · National Institutes of Health · closes November 6, 2026
Advanced Development and Validation of Emerging Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed)
RFA-CA-27-002 · National Institutes of Health · closes November 10, 2026
Early-Stage Innovative Technology Development for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed)
RFA-CA-27-001 · National Institutes of Health · closes November 10, 2026

Same-day alerts, matched to you

The free digest is weekly — the same list for everyone. Members get every open federal grant scored to their organization — and an alert the day a real match posts: we read every new posting the day it opens. Free for 30 days, then $29/mo. Card required, cancel any time before day 31.

Not ready for a subscription? A one-time Fit Report — $29 — scores every open federal grant to your organization once, by email within one business day.

See pricing